Sareum Holdings PLC (LON:SAR)

Sareum Holdings PLC (LON:SAR)


Share Price
0.39 p
Change
-0.005 (-1.27 %)
Market Cap
£11.98 m
Proactive Investors - Run By Investors For Investors

Sareum Holdings PLC

Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.

EPIC: SAR
Market: AIM:SAR
52-week High/Low: 0.930p / 0.380p
Sector: Pharma & Biotech
Market Cap: £11.98 m
Website: www.sareum.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Sareum Holdings PLC


1550850611_CancerHeadline.jpg
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

Sareum Holdings PLC Snapshot

 

Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

Approach

Benefit

Pursue multiple programmes
  • Increase potential success rate
  • Mitigate development risk
Seek collaboration partners
  • Spread financial cost and risk
  • Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development

  • Minimise ongoing development risk
  • Move up value chain
  • Potential for higher deal values

 

 

Overview

Sareum's pipeline is built on the drug discovery expertise of its founders, particularly in the field of cancer.

Sareum operates a collaborative and outsourced business model. All our laboratory-based research is carried out in the laboratories of collaborators or third-party providers. This enables us to access drug discovery expertise throughout the world with a very flexible cost base.

Discovery Programmes Jun15

Click here for our latest research update

Drug Discovery

Discovery Platform

Autoimmune - TYK2 Kinase

Cancer - TYK2 Kinase

Other Programmes

 

 

Stephen Parker DPhil, MBA - Non-executive Chairman
Dr Stephen Parker, aged 60, has a career in the healthcare and pharma sector that spans over 30 years, including six years in the City in advisory roles. He has sector corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners and has previously held roles as a partner at Celtic Pharma and Chief Financial Officer of Oxford GlycoSciences. Stephen is also a Non-executive Director at Silence Therapeutics plc.

Tim Mitchell PhD - Founder and CEO
Dr Tim Mitchell, aged 58, has a wide breadth of management, business and research expertise gained over 30 years in the biotech, large pharmaceutical and research service companies.

He is the inventor of Oblean® (cetilistat) for which Takeda have obtained sales approval in the Japanese market for the treatment of obesity with complications.

Prior to co-founding Sareum he was Director of Structure-Based Discovery at Millennium Pharmaceuticals, Director of Computational Chemistry at Cambridge Discovery Chemistry, and Team Leader at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.

John Reader PhD - Founder and CSO
Dr John Reader, aged 52, has over 25 years' experience within the industry. His previous roles include Associate Director, Chemical Technologies at Millennium Pharmaceuticals Research and Development Ltd, Pharmacopeia Inc., and Cambridge Discovery Chemistry.

John has an excellent track record of delivering successful drug research projects. He has authored or co-authored many publications and patents on small molecule drug discovery. John is a member of the EPSRC Peer Review College and has a PhD in Chemistry and a BSc in Applied Chemistry.

Michael Owen PhD - Non-executive Director
Dr Michael Owen, aged 67, has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. He is the co-founder and first CSO of Kymab Ltd, a biopharmaceutical company based in Cambridge, UK, prior to which he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Dr Owen currently serves on the boards of several public and private biotechnology companies in the UK, Europe and the USA, including Avacta Group plc, ReNeuron plc, GammaDelta Therapeutics and Zealand Pharma A/S. He is also the Chairman of Ossianix Inc. In addition, Dr Owen is Chairman of ReNeuron’s and Avacta’s scientific advisory boards, an advisor to Abingworth LLP and was until recently an advisor to the CRT Pioneer Fund. Dr Owen received a MA from Oxford University and a PhD from Cambridge University, and is an elected member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.

Clive Birch - Non-executive Director
Clive Birch, aged 65, is an Independent Non-Executive Director of Cambridge Innovation Capital plc, a Cambridge-based builder of technology and healthcare companies. He is a retired partner of PricewaterhouseCoopers where his role was that of an auditor and reporting accountant with an industry specialism in early stage technology and healthcare companies. He was also part of the teams involved in fund raising and listing those clients on various markets. Mr Birch was also partner in charge of PwC’s Cambridge office for 15 years up to 2010, during which time he was responsible for all aspects of that stand-alone business. Mr Birch is a Governor of Birkbeck College, part of London University.

Scientific Advisory Board
Harry Finch PhD

Dr Finch has many years’ experience in the Pharmaceutical industry and is currently Executive Vice President at Pulmagen Therapeutics. He was previously Executive VP of Argenta Discovery, a Director at RiboTargets and spent 24 years at GlaxoSmithKline and its predecessor companies, latterly as Director of Chemistry for UK Research & Development.

Harry has extensive experience in a wide range of therapeutic areas. He was a co-inventor of Salmeterol (Serevent; GSK), a successful long-acting bronchodilator for asthma and has 45 patents and 49 publications to his name.

Bob Jackson PhD
Dr Jackson was formerly Chief Scientific Officer at the cancer drug discovery company, Cyclacel Limited. Prior to that, he held senior research positions at Celltech, Agouron, DuPont and Warner-Lambert. Dr Jackson has led teams that have developed 26 compounds to clinical trials, including the Aurora Kinase inhibitor CYC116, and gained his PhD in biochemistry from the University of London.

Head office

Sareum Limited.
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge
CB22 3FX
United Kingdom

tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
 

Broker
Hybridan LLP
20 Ironmonger Lane
London
EC2V 8EP
www.hybridan.com

 

Registrars
Capita Asset Services
The Registry
34 Beckenham Rd
Beckenham
Kent  BR3 4TU
www.capitaregistrars.com

 

Auditor
Shipleys LLP
10 Orange Street
Haymarket
London
WC2H 7DQ
www.shipleys.com

 

Nominated Adviser
WH Ireland Limited
24 Martin Lane
London
EC4R 0DR
www.wh-ireland.co.uk

 

Solicitors
Taylor Vinters
Merlin Place
Milton Road
Cambridge
CB4 0DP
www.taylorvinters.com

 

Financial PR
Citigate Dewe Rogerson
3 London Wall Buildings
London EC2M 5SY
www.citigatedewerogerson.co.uk

Columns Including SAR

VIEW ALL

Market Reports Including SAR

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use